COMP <GO>
LIVN vs MDT // EV/EBITDA & P/E VALUATION
LivaNova PLC (NASDAQ) VS. Medtronic plc. (NYSE) • 15-METRIC TALLY: LIVN 4
— MDT 8
▲ EV/EBITDA & P/E VALUATION LEADER: LIVN
LAST: $78.97 (-2.81%) • MKT CAP: $4.48B
valuation
15.6x
LAST: $96.54 (-0.59%) • MKT CAP: $124.22B
valuation
17.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LIVN VS. MDT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LIVN | MDT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 67.70% | 65.00% | +2.70 | LIVN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 17.30% | 7.80% | +9.50 | LIVN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 15.6x | 17.4x | -1.80 | LIVN | /valuation <GO> |
| Free Cash Flow Yield | 3.87% | 4.37% | -0.50 | MDT | /fcf-yield <GO> |
| Operating Margin | 14.40% | 17.80% | -3.40 | MDT | /operating-margins <GO> |
| Net Profit Margin | -17.50% | 0.00% | -17.50 | MDT | /net-margins <GO> |
| Revenue Growth (YoY) | 10.70% | 8.40% | +2.30 | LIVN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.93% | -2.93 | MDT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 3.08 | -0.87 | MDT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | MDT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.2 | 61.8 | -3.60 | MDT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.91 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.48B | $124.22B | -$119.74B | MDT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LIVN REV | MDT REV | LIVN GROSS % | MDT GROSS % | LIVN FCF | MDT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.39B | $36.36B | 67.7% | 65.0% | $173.3M | $5.43B |
| FY 2024 | $1.25B | $33.54B | 68.1% | 65.3% | $135.9M | $5.18B |
| FY 2023 | $1.15B | $32.36B | — | — | $74.9M | $5.33B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LIVN // BETA —
MDT // BETA 0.91